Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, Vilsbøll T.

PLoS One. 2016 Nov 11;11(11):e0166125. doi: 10.1371/journal.pone.0166125.

2.

Prognostic Factors in Patients Hospitalized with Diabetic Ketoacidosis.

Agarwal A, Yadav A, Gutch M, Consul S, Kumar S, Prakash V, Gupta AK, Bhattacharjee A.

Endocrinol Metab (Seoul). 2016 Sep;31(3):424-432. doi: 10.3803/EnM.2016.31.3.424.

3.

Modified Atkins diet in advanced malignancies - final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System.

Tan-Shalaby JL, Carrick J, Edinger K, Genovese D, Liman AD, Passero VA, Shah RB.

Nutr Metab (Lond). 2016 Aug 12;13:52. doi: 10.1186/s12986-016-0113-y. Erratum in: Nutr Metab (Lond). 2016;13(1):61.

4.

Tacrolimus-Induced Diabetic Ketoacidosis and Effect of Switching to Everolimus: A Case Report.

Tuğcu M, Kasapoğlu U, Boynueğri B, Can Ö, Gökçe AM, Ruhi Ç, Titiz M.

Transplant Proc. 2015 Jun;47(5):1528-30. doi: 10.1016/j.transproceed.2015.04.075.

PMID:
26093759
5.

Amylase, isoamylase and macroamylase.

Goldberg DM, Spooner RJ.

Digestion. 1975;13(1-2):56-75. Review.

PMID:
1104398

Supplemental Content

Loading ...
Support Center